利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.015 秒)

    Growth Hormone Secretagogue Receptor 1A Ligands
    2.
    发明申请
    Growth Hormone Secretagogue Receptor 1A Ligands 审中-公开
    生长激素促分泌素受体1A配体

    公开(公告)号：US20080300180A1

    公开(公告)日：2008-12-04

    申请号：US11720477

    申请日：2005-11-29

    申请人： Hans T. Schambye ,  Birgitte Holst Lange ,  Peter Holme Jensen

    发明人： Hans T. Schambye ,  Birgitte Holst Lange ,  Peter Holme Jensen

    IPC分类号： A61K9/127 ,  A61K38/18 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  C07K7/00 ,  C07K5/00 ,  C07K14/475 ,  A61P3/00

    CPC分类号： C07K5/1016 ,  C07K5/0812 ,  C07K5/101 ,  C07K14/60

    摘要： The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

    摘要翻译： 本发明涉及新的生长激素促分泌素受体1A（GHS-R 1A）配体，以及包含任何新的GHS-R1A配体的药物组合物。 配体适用于广泛的应用，因此本发明还涉及根据本发明的GHS-R1A配体在制备用于治疗有需要的个体的药物中的用途。 另一方面，本发明涉及治疗有此需要的个体的方法，包括向所述个体施用本文公开的一种或多种GHS-R1A配体，例如， 用于治疗癌症恶病质。

    Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
    4.
    发明申请
    Use Of Secretagogue For The Teatment Of Ghrelin Deficiency 审中-公开
    使用秘书处的Ghrelin缺乏症

    公开(公告)号：US20080171700A1

    公开(公告)日：2008-07-17

    申请号：US11578135

    申请日：2005-04-07

    申请人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

    发明人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

    IPC分类号： A61K38/25 ,  A61P5/00 ,  A61P3/00 ,  A61P3/04

    CPC分类号： A61K38/25

    摘要： The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency. Furthermore, the present invention relates to the use of a secretagogue, such as a ghrelin-like compound, for the production of a medicament for preventing weight increase in an individual either: a) being converted from a hyperthyroidic state to euthyroid state, or b) in remission from being converted from a hyperthyroidic state to euthyroid state.

    摘要翻译： 本发明涉及生长激素（GH）促分泌素如生长素释放肽样化合物在个体中用于预防或治疗生长素释放肽缺乏症和/或与之相关的不良症状的药物的用途 有获得由医疗和/或病理状况引起的部分或完全的生长素释放肽缺乏的风险。 本发明还涉及促分泌素化合物在制备用于预防或治疗以下中的一种或多种的药物中的用途：脂肪量的损失，瘦体重的减少，体重减轻，恶病质，食欲不振，免疫功能障碍 ，营养不良，睡眠模式紊乱，困倦，减少肠道吸收和/或肠道运动问题，或者有遭受生长素释放肽缺乏症的个体。 此外，本发明涉及促分泌素如生长素释放肽样化合物在制备用于预防个体体重增加的药物中的用途：a）从甲状腺功能亢进状态转变为甲状腺功能状态，或b ）缓解从甲状腺功能亢进状态转变为甲状腺功能状态。